114 related articles for article (PubMed ID: 35253190)
1. Leptin involvement in the survival of pancreatic adenocarcinoma patients with obesity and diabetes.
Man T; Seicean R; Lucaciu L; Leucuta D; Ilies M; Iuga C; Petrusel L; Seicean A
Eur Rev Med Pharmacol Sci; 2022 Feb; 26(4):1341-1349. PubMed ID: 35253190
[TBL] [Abstract][Full Text] [Related]
2. Serum JAK/STAT profile is related to the IL expression but not with the outcome in pancreatic adenocarcinoma patients.
Petrusel L; Ilies M; Leucuta D; Rusu I; Seicean A; Iuga C; Seicean R
Cell Mol Biol (Noisy-le-grand); 2021 Nov; 67(3):107-112. PubMed ID: 34933726
[TBL] [Abstract][Full Text] [Related]
3. High levels of serum glypican-1 indicate poor prognosis in pancreatic ductal adenocarcinoma.
Zhou CY; Dong YP; Sun X; Sui X; Zhu H; Zhao YQ; Zhang YY; Mason C; Zhu Q; Han SX
Cancer Med; 2018 Nov; 7(11):5525-5533. PubMed ID: 30358133
[TBL] [Abstract][Full Text] [Related]
4. Phosphoglycerate Mutase 1 (PGAM1) Promotes Pancreatic Ductal Adenocarcinoma (PDAC) Metastasis by Acting as a Novel Downstream Target of the PI3K/Akt/mTOR Pathway.
Liu X; Tan X; Liu P; Wu Y; Qian S; Zhang X
Oncol Res; 2018 Aug; 26(7):1123-1131. PubMed ID: 29386088
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator activated receptors at the crossroad of obesity, diabetes, and pancreatic cancer.
Polvani S; Tarocchi M; Tempesti S; Bencini L; Galli A
World J Gastroenterol; 2016 Feb; 22(8):2441-59. PubMed ID: 26937133
[TBL] [Abstract][Full Text] [Related]
6. Pancreatic ductal adenocarcinoma: Prognostic indicators of advanced disease.
Kruger D; Lahoud N; Yako YY; Devar J; Smith M
PLoS One; 2022; 17(1):e0262439. PubMed ID: 35020761
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis of the transcriptional expressions and prognostic value of S100A family in pancreatic ductal adenocarcinoma.
Li HB; Wang JL; Jin XD; Zhao L; Ye HL; Kuang YB; Ma Y; Jiang XY; Yu ZY
BMC Cancer; 2021 Sep; 21(1):1039. PubMed ID: 34530774
[TBL] [Abstract][Full Text] [Related]
8. Adipose Triglyceride Lipase (ATGL) Expression Is Associated with Adiposity and Tumor Stromal Proliferation in Patients with Pancreatic Ductal Adenocarcinoma.
Grace SA; Meeks MW; Chen Y; Cornwell M; Ding X; Hou P; Rutgers JK; Crawford SE; Lai JP
Anticancer Res; 2017 Feb; 37(2):699-703. PubMed ID: 28179319
[TBL] [Abstract][Full Text] [Related]
9. HIF-2α regulates non-canonical glutamine metabolism via activation of PI3K/mTORC2 pathway in human pancreatic ductal adenocarcinoma.
Li W; Chen C; Zhao X; Ye H; Zhao Y; Fu Z; Pan W; Zheng S; Wei L; Nong T; Li Z; Chen R
J Cell Mol Med; 2017 Nov; 21(11):2896-2908. PubMed ID: 28544376
[TBL] [Abstract][Full Text] [Related]
10. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
11. Lower plasma levels of glucose-dependent insulinotropic peptide (GIP) and pancreatic polypeptide (PP) in patients with ductal adenocarcinoma of the pancreas and their relation to the presence of impaired glucoregulation and weight loss.
Škrha J; Bušek P; Uhrová J; Hrabal P; Kmochová K; Laclav M; Bunganič B; Frič P
Pancreatology; 2017; 17(1):89-94. PubMed ID: 28027898
[TBL] [Abstract][Full Text] [Related]
12. Identification of ANXA1 as a lymphatic metastasis and poor prognostic factor in pancreatic ductal adenocarcinoma.
Liu QH; Shi ML; Bai J; Zheng JN
Asian Pac J Cancer Prev; 2015; 16(7):2719-24. PubMed ID: 25854353
[TBL] [Abstract][Full Text] [Related]
13. Comparison of ILK and ERP29 expressions in benign and malignant pancreatic lesions and their clinicopathological significances in pancreatic ductal adenocarcinomas.
Zhang K; Yao H; Yang Z; Li D; Yang L; Zou Q; Yuan Y; Miao X
Clin Transl Oncol; 2016 Apr; 18(4):352-9. PubMed ID: 26887611
[TBL] [Abstract][Full Text] [Related]
14. DEK protein overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma.
Sun J; Bi F; Yang Y; Zhang Y; Jin A; Li J; Lin Z
Oncol Rep; 2017 Feb; 37(2):857-864. PubMed ID: 27959420
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma.
Chung HW; Lim JB
J Transl Med; 2014 Apr; 12():102. PubMed ID: 24745825
[TBL] [Abstract][Full Text] [Related]
16. Clinical Implications of NRAS Overexpression in Resectable Pancreatic Adenocarcinoma Patients.
Martinez-Useros J; Li W; Georgiev-Hristov T; Fernandez-Aceñero MJ; Borrero-Palacios A; Perez N; Celdran A; Garcia-Foncillas J
Pathol Oncol Res; 2019 Jan; 25(1):269-278. PubMed ID: 29101736
[TBL] [Abstract][Full Text] [Related]
17. Expression and prognosis value of SHP2 in patients with pancreatic ductal adenocarcinoma.
Zheng J; Huang S; Huang Y; Song L; Yin Y; Kong W; Chen X; Ouyang X
Tumour Biol; 2016 Jun; 37(6):7853-9. PubMed ID: 26695153
[TBL] [Abstract][Full Text] [Related]
18. Serum platelet factor 4 is an independent predictor of survival and venous thromboembolism in patients with pancreatic adenocarcinoma.
Poruk KE; Firpo MA; Huerter LM; Scaife CL; Emerson LL; Boucher KM; Jones KA; Mulvihill SJ
Cancer Epidemiol Biomarkers Prev; 2010 Oct; 19(10):2605-10. PubMed ID: 20729288
[TBL] [Abstract][Full Text] [Related]
19. IL-8-Positive Tumor-Infiltrating Inflammatory Cells Are a Novel Prognostic Marker in Pancreatic Ductal Adenocarcinoma Patients.
Fang Y; Saiyin H; Zhao X; Wu Y; Han X; Lou W
Pancreas; 2016; 45(5):671-8. PubMed ID: 26495785
[TBL] [Abstract][Full Text] [Related]
20. Reduced mean platelet volume levels predict shorter survival in patients with resectable pancreatic ductal adenocarcinoma and type 2 diabetes.
Yin JB; Li N; Cui MM; Wang X; Wang RT
BMC Gastroenterol; 2020 May; 20(1):143. PubMed ID: 32393273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
